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Abstract: Early detection of cancer holds high promise for reducing cancer-related mortality. 
Detection of circulating tumor-specific nucleic acids holds promise, but sensitivity and specificity 
issues remain with current technology. We studied cell-free RNA (cfRNA) in patients with non-
small cell lung cancer (NSCLC; n = 56 stage IV, n = 39 stages I-III), pancreatic cancer (PDAC, n = 20 
stage III), malignant melanoma (MM, n = 12 stage III-IV), urothelial bladder cancer (UBC, n = 22 
stage II and IV), and 65 healthy controls by means of next generation sequencing (NGS) and real-
time droplet digital PCR (RT-ddPCR). We identified 192 overlapping upregulated transcripts in 
NSCLC and PDAC by NGS, more than 90% of which were noncoding. Previously reported 
transcripts (e.g., HOTAIRM1) were identified. Plasma cfRNA transcript levels of POU6F2-AS2 
discriminated NSCLC from healthy donors (AUC = 0.82 and 0.76 for stages IV and I–III, 
respectively) and significantly associated (p = 0.017) with the established tumor marker Cyfra 21-1. 
cfRNA yield and POU6F2-AS transcript abundance discriminated PDAC patients from healthy 
donors (AUC = 1.0). POU6F2-AS2 transcript was significantly higher in MM (p = 0.044). In summary, 
our findings support further validation of cfRNA detection by RT-ddPCR as a biomarker for early 
detection of solid cancers. 
Keywords: liquid biopsy; cfRNA; cancer; ddPCR; NGS; POU6F2-AS2; early detection 
 
1. Introduction 
Lung cancer (LC) is a leading cause of all cancer-related deaths in men and women worldwide, 
accounting for more than 14% of all newly diagnosed cancers [1,2]. Although the understanding of 
lung cancer pathobiology has significantly improved over the last decades, disease prognosis 
continue to remain poor with a five-year survival rate of only 17% and 7% for non-small cell lung 
cancer (NSCLC) and small cell lung cancers (SCLC), respectively [3,4]. As with other cancers, poor 
disease prognosis is partially attributed to late stages at diagnosis, given that there are very few early 
symptoms [5,6]. Indeed, about 67% of all lung cancer cases are diagnosed at a late stage, leading to 
high mortality rates [6]. Lung cancer treatment is stage-specific. Early stage disease (I-II UICC 8th 
edition) can be cured by surgical resection, while locally advanced disease requires multimodal 
treatment, including chemotherapy, radiotherapy, and surgery for selected cases. Recurrent 
metastatic disease is treated with palliative systemic therapy [7–9]. When diagnosed at an early stage, 
patients with NSCLC have a 5-year survival rate of about 71%, as opposed to less than 2% for patients 
diagnosed with stage IV disease [10]. Early diagnosis may thus improve patient outcome [11].  
To this end, low-dose computed tomography (LDCT) was developed for screening in high-risk 
groups, with a reported sensitivity of about 93% and a 20% reduction in mortality [12,13]. Despite 
this, its wide application is hampered by consideration of cost effectiveness, high rates of false 
positives, risk of developing radiation-related cancers, and over-diagnosis [14,15]. Therefore, there is 
still a considerable unmet need to develop non-invasive complementary biomarkers for early 
detection of lung cancer. 
Currently, protein- and microRNA (miRNA)-based markers are at advanced validation stages 
or already in clinical use [16]. Carcinogen embryonic antigen (CEA) is one of the most widely used 
biomarkers for cancer screening in several entities, including lung cancer. Cytokeratin-19 fragment 
(Cyfra21-1) is also a tumor marker for lung cancer [17,18]. However, high false positive elevated 
levels of these markers in benign disease and restricted sensitivity limit their use for routine screening 
for early diagnosis of cancer [6,18–20]. Immune-based markers are attractive. However, they show 
very low sensitivity. For example, one commercially available autoimmune antibodies test showed 
only 36% sensitivity but 91% specificity in NSCLC [21]. miRNAs have been also tested in several 
studies on a plethora of platforms, including microarray, next-generation sequencing (NGS), and RT-
PCR. While NGS and microarray-based approaches are highly reproducible and specific, they lack 
the accuracy and sensitivity required for early detection, especially in the context of low copy 
transcripts [22].  
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The most attractive non-invasive solution for the identification of biomarkers for early detection 
of lung cancer is through simple blood test [23]. To date, very few studies have addressed the utility 
of cell-free RNA (cfRNA) for early diagnosis of cancer, despite previous reports highlighting the 
potential clinical utility of this liquid compartment. Initially identified in patients with malignant 
melanoma [24] and nasopharyngeal carcinoma [25], cfRNA has been reported in several other cancer 
entities, including breast cancer [26], colorectal cancer [27–29], follicular lymphoma [30], and 
hepatocellular carcinoma [31]. Recently, cfRNA has been used for non-invasive determination of 
gestational aged with better performance compared with standard techniques [32]. cfRNA is 
therefore a potential source of analyte for early detection biomarker discovery. In light of the 
aforementioned, we herein report on the use of cfRNA for early detection of cancer in solid cancers 
with an application to lung, pancreas, bladder, and skin cancers. We use a combination of NGS-based 
cfRNA profiling and real-time digital droplet PCR (RT-ddPCR) for the analysis of cfRNA for early 
diagnosis of solids cancers. 
2. Results 
2.1. Patients and Baseline Characteristics  
In total, we analyzed cfRNA in blood samples from 153 patients with four different cancer 
entities and 65 healthy donors (Table 1) using total cfRNA-sequencing and RT-ddPCR. First, a pilot 
cohort comprising 11 stage IV NSCLC patients, 4 stage IV PDAC patients, and 4 healthy donors 
(cfRNA-seq) was studied. In 12 of 15 sequenced samples, more than 50 million reads were obtained, 
and about 40 million reads were obtained for three other samples. More than 70% of reads could be 
uniquely mapped in all samples, and protein-coding genes were covered by about 5% of reads in all 
sequenced samples (Supplementary Figure S1). This was followed by a validation cohort of 84 
NSCLC, 12 MM, 20 PDAC, 22 UBC patients, and 61 healthy donors. Tissue expression of specific 
RNA transcripts was studied in formalin-fixed paraffin-embedded (FFPE) tissue samples from 18 
NSCLC and 9 healthy lungs by RT-ddPCR. 
Table 1. Baseline clinic-pathological parameters of the study population. 
Variable 
Discovery Cohort Validation Cohort 
NSCLC PDAC NSCLC PDAC Melanoma Bladder 
Total, n 11 4 84 20 12 22 
Age             
Median (SD) 65 (8.0) 66 (8.7) 66 (9.2) 70 (9.6) 54 (13.5) 70 (10.3) 
Gender, n (%)             
Male 4 (36) 2 (50) 42 (50) 11 (55) 7 (60) 18 (80) 
Female 7 (64) 2 (50) 42 (50) 9 (45) 5 (40) 4 (20) 
Smoking, n (%)             
Never smoker - - 5 (6) - - - 
Past smoker - - 18 (21) - - - 
Current smoker - - 14 (17) - - - 
Unknown 11 (100) 4 (100) 47 (56) 20 (100) 12 (100) 22 (100) 
ECOG status             
0 8 (70) - 64 (76) - 10 (83) - 
1 3 (30) - 16 (19) - 2 (17) - 
2 - - 1 (1) - - - 
Unknown - 4 (100) 3 (4) 20 (100) - 22 (100) 
Stage             
Early a  - 1 (25) 39 (46)   - 6 (30) 
Late 11 (100) 3 (75) 45 (54) 20 (100) 12 (100) 16 (70) 
CEA              
<ULN 1 (1) - 9 (11) - - - 
≥ULN 10 (99) - 32 (38) - - - 
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Not done - 4 (100) 43 (51) 20 (100) 12 (100) 22 (100) 
Cyfra21-1             
<ULN 3 (30) - 5 (6) - - - 
≥ULN 8 (70) - 36 (43) - - - 
Not done - 4 (100) 43 (51) 20 (100) 12 (100) 22 (100) 
CA 19.9             
<ULN - - - 5 (25) - - 
≥ULN - 2 (50) - 15 (75) - - 
Not done 11 (100) 2 (50) 84 (100) - 12 (100) 22 (100) 
LDH             
<ULN - - - - 10 (83) - 
≥ULN - 3 (75) - - 2 (17) - 
Not done 11 (100) 1 (25) 84 (100) 20 (100) - 22 (100) 
a Stage I-II-III in case of NSCLC, stage I-II in case of PDAC, melanoma and bladder; NSCLC, non-
small cell lung cancer; PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation; ECOG, 
Eastern Cooperative Oncology Group; ULN, upper limit of normal; CEA ULN: 2.6 ng/mL; Cyfra21-1 
ULN: 2.1 ng/mL; CA 19.9 ULN: 37 U/mL; LDH ULN: 247 IU/L. 
2.2. Epithelial Cells and Monocytes Differentiate Patient and Healthy cfRNA 
Most solid tumors, including lung adenocarcinomas, mainly develop from epithelial cells. We 
hypothesized that, if the tumor contributes substantially to the cfRNA pool in patients, the transcript 
signal accounted for by epithelial cells in patients should be significantly higher in patients than in 
controls.  
To test this, we investigated the contribution of different cell types to the cfRNA pool and if 
contributions from particular cell types could differentiate patient samples from healthy samples. We 
thus performed a cell-type signal deconvolution in which we included reference maps from 45 
different cell types. As seen from the heatmap in Figure 1A, signal contribution was similar from most 
cell types. However, there was a significantly higher (false discovery rate = 0.04) contribution from 
epithelial cells in cancer patients compared with healthy controls. Similarly, monocytes contributed 
significantly (FDR = 0.02) higher in healthy donors compared with patients (Figure 1B,C). Indeed, in 
a comparison between patient and healthy samples for epithelial, endothelial, and monocytes cell 
signatures, we identified epithelial cells and monocytes, but not endothelial cells, to show different 
transcript levels in patients and controls (Figure 1B,C)  
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Figure 1. Epithelial cells contribute more to the cfRNA pool of lung cancer patients than controls. (A) 
Cell type deconvolution of 45 different cell types of transcriptomes derived from NSCLC patients (n 
= 7, stage IV) and healthy donors (n = 4). Data represents normalized odds ratios comparing number 
of enriched cell type-specific genes with random enrichment for each sample (rows) and cell type 
(columns). (B) Box plots represent healthy controls (blue) and NSLC patients (red) for epithelial, 
monocyte, and endothelial cell signatures in plasma. Data are derived from A; q-values represent the 
false discovery rate-adjusted p values. Only epithelial and monocyte signatures had a q-value < 0.05. 
(C) Hierarchical clustering of all epithelial and monocyte-specific signature data from (A) separate 
NSCLC patients. 
2.3. cfRNA Sequencing Identifies Common Transcripts Upregulated in Cancer Patients 
In the pilot cfRNA sequencing study, as shown in Supplementary Table 1, pairwise differential 
gene expression between plasma from NSCLC patients and healthy controls led to the identification 
of 605 upregulated transcripts (log2FC ≥ 1, FDR < 0.05). A total of 390 transcripts were selectively 
upregulated (log2FC ≥ 1, FDR < 0.05) in cfRNA from PDAC patients (Supplementary Table S2). A 
subset of 192 genes were overlappingly upregulated in plasma cfRNA derived from both PDAC and 
NSCLC patients (Figure 2a,b). Non-coding transcripts significantly contributed to those commonly 
upregulated genes, with pseudogenes, antisense transcripts, and long noncoding RNAs representing 
49.2%, 19.2%, and 11.9%, respectively. Protein coding genes accounted for only 5.7% (Figure 2c).  
Gene expression data from NSCLC tumors was downloaded from the gene expression omnibus 
(GEO). Pair-wise differential gene expression was performed to identify genes that were upregulated 
in tumor tissue compared with non-tumor tissue. We identified 3060 genes to be upregulated in 
tumor tissue (log2FC ≥ 1 and FDR < 0.05). In order to identify tumor-relevant cfRNA transcripts, we 
intersected the list of upregulated genes in tumor tissue and plasma. This identified 24 upregulated 
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transcripts (Figure 2d), including the previously reported HOTAIRM1 [33], (Supplementary Figure S2A). 
HOTAIRM1 was upregulated in plasma but not in tumor tissue from NSCLC patients (Figure S2B). 
Conversely, the NSCLC-associated transcript MALAT1 was highly expressed in plasma from healthy 
donors but not NSCLC patients (Figure S2c,d) 
We identified a previously reported cancer-related long non-coding RNA (lncRNA), POU6F2-
AS2, to be upregulated in both lung cancer cfRNA and tumor tissue, as well as other transcripts, such 
as the lncRNA AC022126.1 (Figure 2d–f). LncRNA POU6F2-AS2 is known to be associated with 
another solid tumor, esophageal squamous cell carcinoma [34]. Hence, we selected POU6F2-AS2 and 
AC022126.1 to further explore the utility of detection of cfRNA transcripts as cancer biomarkers. 
 
Figure 2. Total cfRNA transcriptome profiling identify potential cancer biomarkers. (a) Heatmap of 
genes upregulated in non-small cell lung cancer (NSCLC; n = 11 stage IV patients), and pancreatic 
ductal adenocarcinoma (PDAC; n = 4 stage IV patients) compared with healthy (n = 4 blood donors) 
plasma samples. Heatmap is plotted based on 192 common genes. (b) Venn diagram of the number 
of common upregulated genes in NSCLC and PDAC. (c) Pie chart showing the distribution of 
transcript types across the common upregulated genes. (d) Heatmap showing upregulated genes in 
NSCLC (n = 11) and healthy (n = 4) plasma samples based on the expression profiles of 24 genes 
differentially expressed in cfRNA and tumor-derived RNA. Candidate genes were derived from 
analyses of tumor/healthy tissue (GSE 81089 dataset) and RNA-Seq data from this study. (e) Volcano 
plots for differentially expressed genes in GSE 81089 dataset and (f) this study. Genes that passed the log2 
fold change ≥ 1 and FDR < 0.05 criteria are highlighted in blue (down-regulation) or yellow (up-regulation). 
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2.4. The lncRNAs POU6F2-AS2 and AC022126.1 Are Upregulated in Plasma from NSCLC Patients 
POU6F2-AS2 was identified among other (Figure 2d) as a cancer-associated transcript by 
cfRNA-seq (Figure 3A). Using RT-ddPCR, we could confirm POU6F2-AS2 as a tumor-associated 
transcript in plasma samples from 45 stage IV NSCLC patients and 39 stage I–III NSCLC patients 
(Figure 3B). There was no correlation between POU6F2-AS2 expression and NSCLC stage (Figure 
3C,D; AUC = 0.82 and 0.76; for late stage and early stage diseases, respectively) (Supplementary Figure 
S3A,B). Furthermore, POU6F2-AS2 expression was similar in all stages of NSCLC and could not 
discriminate early stage from late stage disease (AUC = 0.42) (Supplementary Figure S2C). In contrast, 
the lncRNA AC022126.1 transcripts failed to discriminate cfRNA from cancer patients and healthy 
donors in our validation cohort (Figure 3E,F). 
 
Figure 3. POU6F2-AS2 and AC022126.1 cfRNA transcripts are highly expressed in lung cancer. (A) 
Plasma expression of POU6F2-AS2 as profiled by total cfRNA sequencing in healthy donors (n = 4) 
and NSCLC (n = 11). Plasma expression of POU6F2-AS2 as profiled by real-time digital droplet PCR 
(RT-ddPCR) (B). in healthy donors (n = 37) and NSCLC (n = 84) patients (C). in healthy donors (n = 
37) and early stage NSCLC (n = 39) patients (D). in healthy donors (n = 37) and late stage NSCLC (n = 
45) patients. Plasma expression of AC022126.1 as profiled by (E). total cfRNA sequencing (n = 4 heathy 
donors; n = 11 NSCLC patients) and (F). by ddPCR (n = 28 heathy donors; n = 84 NSCLC patients). In 
A–F scatter dot-plots, the line indicates the mean; Student’s t-test p values are indicated. 
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2.5. High POU6F2-AS2 Levels is Associated with Higher Cyfra 21.1 Levels 
Levels of the tumor marker Cyfra21-1 were significantly associated (p = 0.017) with higher 
plasma levels of POU6F2-AS2 (Table 2). No significant association was found between our selected 
cfRNA transcripts and tumor stage, CEA, disease histology, smoking status, gender, and age. 
POU6F2-AS2 cfRNA transcript levels were not correlated with clinical data for other cancer entities 
due to small sample numbers. 
Table 2. Association of POU6F2-AS and AC022162.1 expression with baseline characteristics of 
NSCLC patients in validation cohort. 
Variable N (%) POU6F2-AS2 AC022162.1 
 n (%) mean p mean p 
Age           
< 66 years 38 (45.2) 9.5 
0.686 
9.6 
0.438 ≥ 66 years 46 (54.8) 9.6 9.9 
Gender           
Male 42 (50) 9.8 
0.058 
9.9 
0.430 Female 42 (50) 9.3 9.6 
Smoking       




Past smoker 18 (21) 9.5 10.1 
Current smoker 14 (17) 9.6 9.6 
Unknown 47 (56) 9.7 9.7 
ECOG status           




1 16 (19) 9.9 10.3 
2 1 (1) 10.9 11.4 
Unknown 3 (4) 9.7 9.6 
Histology           




Non-squamous NSCLC 33 (39) 9.5 9.6 
Squamous NSCLC 21 (25) 9.7 9.9 
Other  7 (8) 9.7 9.7 
Stage           




Late (III-IV) 51 (61) 9.7 9.8 
CEA            
< ULN 9 (11) 9.2 
0.371 
9.1 
0.467 ≥ ULN 32 (38) 9.8 9.8 
Not done 43 (51) 9.5 9.9 
Cyfra21-1           
< ULN 5 (6) 8.2 
0.017 
8.3 
0.151 ≥ ULN 36 (43) 9.9 9.9 
Not done 43 (51) 9.5 9.9 
p: student's t-test (2-groups) or 1-way ANOVA (3 or more groups); Mean values represent log2 RNA 
copies/ml plasma; CEA ULN (upper limit of normal): 2.6 ng/ML; Cyfra21-1 ULN (upper limit of 
normal): 2.1 ng/ML; NSCLC, non-small cell lung cancer. 
2.6. Serum cfRNA Concentration Correlates with POU6F2-AS2 Expression 
Transcript abundance can be affected by the overall RNA yield (expressed in ng/mL) from a 
sample. Given that equal volumes of different samples may result in varying amounts of total cfRNA, 
we investigated the effect of input cfRNA amount on absolute transcript counts in plasma and serum. 
cfRNA yield per unit sample volume was higher in PDAC serum and could discriminate patients 
from healthy donors (Supplementary Figures S3D and S4A). Similarly, in PDAC sera, there was a 
very strong correlation (r = 0.98) between the transcript abundance of POU6F2-AS per unit volume 
Cancers 2020, 12, 353 9 of 18 
 
and the total cfRNA yield (Supplementary Figure S4B). In NSCLC plasma samples, there was a weak 
correlation (r = 0.33) between total cfRNA yield and POU6F2-AS2 transcript abundance 
(Supplementary Figure S4C). Similarly, there was no difference in plasma cfRNA yield between 
NSCLC at different stages and between patient and healthy controls (Supplementary Figure S4D).  
Furthermore, the total amount of cfRNA isolated per unit volume of sample was about 4-fold 
lesser in plasma than in serum. This trend was observed in both healthy donor samples and PDAC 
patient samples (Supplementary Figure S5A,B)  
2.7. The lncRNAs POU6F2-AS2 and AC022126.1 Are Upregulated in NSCLC Tissue 
To investigate the tissue expression of candidate transcripts, we used RNA sequencing data from 
publicly available sources and RT-ddPCR validation on RNA isolated from FFPE NSCLC tumor 
tissue samples and adjacent normal lung tissue. In publicly available RNA sequencing data from 
tumor samples, the transcript levels of POU6F2-AS2 was significantly upregulated in tumor-derived 
RNA as compared to non-tumor lung tissue (Figure 4A,B). Interestingly, tumor expression of 
POU6F2-AS2 was independent of NSCLC stage (Figure 4C). Validation by RT-ddPCR analysis of 
RNA from FFPE samples revealed higher POU6F2-AS2 transcript levels in tumor-derived RNA as 
compared to normal lung RNA (Figure 4D). There was no impact of NSCLC stage in terms of 
discrimination between tumor and normal tissue RNA (Figure 4E,F). 
 
Figure 4. POU6F2-AS2 and AC022126.1 transcripts are highly expressed in lung cancer tissue and is 
stage independent. (A) Tissue expression of POU6F2-AS2 as profiled by RNA sequencing in lung 
cancer tissue and adjacent non-tumor lung GSE 81089 dataset). (B) Tissue expression of AC022126.1 
as profiled by RNA sequencing in lung cancer tissue and adjacent non-tumor lung GSE 81089 dataset).  
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(C) Association between POU6F2-AS2 expression and tumor stage in NSCLC tumor tissue samples 
from the GSE 81089 dataset (n = 199 tumor tissue samples and 19 non-tumor lung samples). 
Significance was tested in 1-way ANOVA. (D) Tissue expression of POU6F2-AS2 as profiled by RT-
ddPCR in healthy donors (n = 9) and NSCLC (n = 18) patients, (E) Tissue expression of POU6F2-AS2 
as profiled by RT-ddPCR in healthy donors (n = 9) and early stage NSCLC (n = 12) patients, and (F) 
Tissue expression of POU6F2-AS2 as profiled by RT-ddPCR in healthy donors (n = 9) and late stage 
NSCLC (n = 7) patients. In A–F scatter dot-plots, the line indicates the mean; Student’s t-test p values 
are indicated. 
2.8. POU6F2-AS2 Is Upregulated in Additional Cancers 
We next asked if POU6F2-AS2 transcripts are exclusively upregulated in NSCLC plasma. To this 
end, we analyzed cfRNA isolated from serum samples of 20 additional PDAC, 22 UBC, and 22 healthy 
serum samples. Additionally, we analyzed cfRNA isolated from 12 MM plasma samples. In cfRNA 
from PDAC sera, POU6F2-AS transcript levels were significantly higher in patients than in healthy 
controls (Figure 5B). In malignant melanoma, plasma-derived cfRNA, POU6F2-AS2 transcript levels 
were significantly higher in patients than controls (Figure 5C). No significant difference was observed 
in UBC samples and healthy controls (Figure 5D). 
 
Figure 5. POU6F2-AS2 is highly expressed in cfRNA from other solid tumor entities. (A) Plasma 
expression of POU6F2-AS2 as profiled by total cfRNA sequencing in healthy donors (n = 4) and PDAC 
(n = 4). (B) Expression of POU6F2-AS2 as profiled by RT-ddPCR in healthy donors’ (n = 22) and PDAC 
(n = 20) patients’ sera, (C) Expression of POU6F2-AS2 as profiled by RT-ddPCR in healthy donors’ (n 
= 37) and melanoma (n =12) patients’ plasma, and (D) Expression of POU6F2-AS2 as profiled by RT-
ddPCR in healthy donors’ (n = 22) and and bladder cancer (n = 22) patients’ sera. In (A–D) scatter dot-
plots, the line indicates the mean; Student’s t-test p values are reported.  
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3. Discussion 
Early diagnosis of cancer may improve survival outcome, as it allows for curative surgical 
intervention. Indeed, in lung cancer, the five-year survival rate of patient diagnosed at early stages is 
much higher than patients diagnosed at later stages [35,36]. Identification and validation of non-
invasive biomarkers for early detection of cancer is, therefore, a considerable unmet need. Ideally, a 
biomarker should offer high sensitivity and sufficient specificity in a cost- and time-efficient manner 
to allow for its implementation into routine clinical practice [37]. Early diagnosis of lung cancer using 
LDCT has been shown to reduce mortality about 20% [38]. However, repeated radiation exposure, 
high cost, and high false positive rates represent significant challenges, and better alternatives are 
still needed. 
Liquid biopsy-based test have been approved for detection of EGFR mutation (mutEGFR) in 
metastatic lung cancer [39]. While this represents a significant breakthrough, mutEGFR is only present 
in about 10–40% of all NSCLC cases [40]. Besides, the test targets metastatic patients, thus offering 
little or no chances for early detection for potential curative intervention. Although cfRNA was first 
reported to be present in several cancer entities more than a decade ago [24–31], its diagnostic value 
has not been properly evaluated, especially in cancer. In spite of the fact that several legitimate 
concerns remain regarding the stability of cfRNA, a recent study highlighted the predictive strengths 
of cfRNA in pregnancy [32]. This demonstrates that cfRNA sequencing is feasible in the context of 
biomarker identification.  
The study presented here aimed to explore a previously unexplored liquid biopsy compartment 
with significant opportunities for biomarker discovery. We used two independent highly sensitive 
technologies (next generation sequencing and droplet digital PCR) for profiling and absolute 
quantification of circulating-free and vesicle-encapsulated RNA in serum and plasma samples from 
four different solid tumor entities. Furthermore, we evaluated the expression of selected candidate 
transcripts in a large cohort of tumor samples and adjacent non-tumor tissue. We validated the 
expression pattern of a potential candidate in early and late-stage plasma samples from lung cancer 
patients, as well as tumor/normal tissue samples. Patient mutation status was not considered.  
Unlike tissue-derived RNA, which is predominantly contributed by cells of a specific organ, 
cfRNA is usually contributed by several sources as blood circulates through the body. We performed 
transcript signal deconvolution using reference maps from 45 different cell types and identified a 
distinctive epithelial source of cancer-associated transcripts. Our study reveals that the majority of 
transcripts that are upregulated in cancer patient plasma are in fact non-coding transcripts. Indeed, 
some studies [41,42] have reported non-coding RNAs as liquid biopsy-based biomarkers in cancer. 
Very few coding transcripts were identified, most probably because of endogenous cellular 
degradation of these transcripts following translation by the CNOT complex [43]. Interestingly, we 
identified a previously reported lncRNA species (HOTAIRM1) that is associated with colorectal 
cancer [34,44]. Furthermore, we identified a panel of transcripts that are highly expressed in plasma 
from cancer patients (PDAC and lung cancers). We validated a previously reported cancer-associated 
transcript POU6F2-AS2 in plasma and serum samples from lung cancer, pancreatic ductal 
adenocarcinoma, malignant melanoma, and bladder cancer samples. We showed that plasma and 
tissue transcript levels of certain transcripts correlate to a high degree, demonstrating specificity of 
the plasma marker for malignant tissue. 
We investigated the performance of a candidate marker in early and late stage lung cancer 
patients. The transcript levels of POU6F2-AS2 showed a good diagnostic performance in both early 
and late stage disease with an AUC of 0.82 and 0.76, respectively. This suggests that cfRNA transcript 
indeed may serve as a potential lung cancer biomarker. The association of tumor tissue in such 
discovery studies is of crucial importance, as we found out that the lung cancer associated lncRNA 
MALAT1, which is upregulated in tumor tissue [45] was upregulated in healthy plasma. Since cfRNA 
arises from diverse cellular sources, differential transcript contribution from different sources into 
the cfRNA pool may indeed affect individual transcript abundance. Hence, only transcripts with 
significant or exclusive tumor sources are very likely to be informative. Therefore, we performed cell-
type signal deconvolution on our cfRNA sequencing data. We could show that only signals from 
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epithelial origin could distinguish patients from healthy donors. Additionally, there was a 
significantly high contribution of monocytes to the cfRNA pool in healthy controls compared with 
patients. Furthermore, plasma total cfRNA abundance was similar in healthy donors and lung cancer 
patients plasma of all stages. This suggests that cfRNA abundance in plasma does not affect transcript 
expression patterns. On the other hand, serum derived total cfRNA abundance was significantly 
higher in PDAC serum samples compared with healthy serum. Although the diagnostic value of such 
differences was not explored here, it may represent an opportunity to be exploited. 
While our study does not aim at evaluating the utility of cfRNA in disease surveillance and 
treatment monitoring, it does provide first-hand evidence of the usefulness of cfRNA in early 
diagnosis of solid tumors, especially NSCLC. Most importantly, the cross-entity validation and tumor 
tissue association of selected candidates strengthens the data and opens new opportunities for 
biomarker discovery. Finally, the fact that transcriptomic changes occur relatively faster than 
genomic changes and that cellular transcriptional machinery amplifies analyte molecules improves 
sensitivity and also allows for detection of patients irrespective of the presence or absence of 
measurable genetic alterations.  
4. Materials and Methods 
4.1. Study Design and Patient Population 
Patients analyzed in this study were prospectively recruited at the different study sites, either 
within clinical trials or clinical translational studies. Lung cancer patients were recruited at the 
outpatient unit of the Department of Medical Oncology at the West German Cancer Center, 
University Hospital Essen (stage IV) and at the Ruhrlandklinik (stage I–III) within the framework of 
the CEVIR study (https://www.transcanfp7.eu/index.php/abstract/cevir.html). Patients with either 
borderline or locally advanced but non-metastatic pancreatic ductal adenocarcinoma were recruited 
within the framework of the NEOPLAP prospective, randomized, open-label, phase II clinical trial 
study (https://clinicaltrials.gov/ct2/show/NCT02125136). Samples from bladder cancer patients were 
prospectively collected for an institutional biobank between 2008 and 2013, and samples from 
melanoma patients were collected within standard biobanking procedures at the Department of 
Dermatology of the University Hospital in Essen. Samples from healthy blood donors were obtained 
from blood donors at the Department of Transfusion Medicine, University Hospital Essen. 
In our pilot study, we performed total cfRNA plasma sequencing on 11 NSCLC patients, 4 
PDAC, and 4 healthy blood donors. In the validation study, we performed RT-ddPCR on cfRNA from 
45 stage IV, as well as 39 stage I–III NSCL samples, 20 PDAC, 12 melanoma, 22 bladder cancer, and 
more than 61 healthy donors (serum/plasma). Additionally, RT-ddPCR was performed on a 
retrospective collection of 18 (unmatched to plasma) lung tumor FFPE samples and 9 adjacent non-
tumor lung tissues. The local institutional review boards approved the studies at all sites, and all 
participants provided written informed consent for biomedical research allowing for molecular 
analysis on tissue and plasma samples. (NSCLC: 17-7740-BO, 14-6056-BO, PDAC: 17-7729-BO & 92/14 
ff, MM: 16-7132-BO, UBC: 08-3942). All healthy controls included in the study provided consent for 
the use of their samples for molecular analysis, and ethical approval was obtained from the ethical 
committee at the Medical Faculty of the University of Essen (17-7729-BO). 
4.2. Blood Sampling and Plasma/Serum Preparation 
Blood samples were collected prior to treatment initiation. For plasma preparation, blood 
samples were collected in 7.5 mL EDTA blood tubes (ref # 01.1605.001, Sarstedt, Nümbrecht, 
Germany) and centrifuged at 200 × g for 10 min at 4 °C. The upper phase was then transferred into 2 
mL tubes (cat # 296920064, Neolab, Heidelberg, Germany) and then centrifuged at 800 × g for 10 min 
at 4 °C. Finally, the supernatant was aliquoted into 2-mL tubes and then centrifuged at 16000 × g for 
10 min at 4 °C. The resulting plasma was transferred into new 2-mL tubes and stored at −80 °C until 
cfRNA extraction. When plasma preparation was not possible immediately, the samples were 
immediately kept at 4 °C and processed within 2 h of blood draw. Serum was prepared from blood 
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collected in 10-mL BD Vacutainer® plus plastic tubes (cat # 366430, BD, Heidelberg, Germany). Blood 
samples were allowed to stand at room temperature for 30 min and then centrifuged at 2000 × g for 
10 min at 4 °C. The resulting serum was aliquoted and stored at −80 °C until cfRNA isolation. 
4.3. cfRNA Isolation and Quantification 
Cell-free RNA was isolated using the Plasma/Serum RNA Purification Mini Kit (Cat. 5,5000, 
Norgen Biotek, Canada), which isolates both cfRNA and vesicle-encapsulated RNA, following the 
manufacturer’s instruction with slight modifications. Briefly, plasma/serum samples were allowed to 
thaw on ice and then 200 µL of plasma/serum cleared at 16000 × g for 2 min at 4 °C and the supernatant 
transferred into a new tube. The precleared plasma/serum was then combined with 3 volumes (600 
µL) of Lysis buffer A, containing 0.01% β-mercaptoethanol and mixed by vortexing. To one volume 
of lysate (800 µL), an equal amount of absolute ethanol was added and mixed by vortexing for 5 s. 
The lysate was then loaded onto a mini column and allowed to stand at room temperature for 10 min 
for RNA binding. The columns were then centrifuged at 6000 rpm for 3 min. The columns were then 
washed 3× with 400 µL of wash buffer A and dried by centrifugation at 1,3000 rpm for 2 min. RNA 
was eluted in 25 µL of elution buffer A after incubation on the column for 15 min. The RNA 
concentration was measured using a Quantus fluorometer (Promega, Madison, Fitchburg WI., USA), 
and samples were stored at –80°C until analyzed. 
4.4. RNA Isolation from Tumor/Non-Tumor Tissue 
RNA isolation was performed using the simplyRNA tissue kit (cat# AS1340, Promega 
Corporation), following manufacturer’s instructions. Briefly, tissue pieces were cut on dry ice with a 
sterile scalpel blade and placed in a Precellys lysing kit tube (cat# P000912-LYSKO-A, Bertin Corp, 
Montigny-le Bretonneux, France). Sample homogenization buffer containing 0.02% thioglycerol was 
added, and the tube was placed into a precooled Precellys device. The Precellys machine was then 
programmed to rupture hard tissue for 2 min. After the tissue was completely disintegrated, 200 µL 
of lysis buffer was added to the cell suspension and then transferred into a cartridge of Maxwell 
SimplyRNA tissue kit (cat# AS1340, Promega Corporation), and 5 µL of DNase 1 was added to the 
appropriate well of the cartridge. RNA isolation was done following the installed kit-specific protocol 
and eluted in 60 µL of nuclease-free water. Quantification was carried out using a Quantus 
fluorometer (Promega), and samples were stored at −80 °C until analyses. 
4.5. RNA Isolation from FFPE Sections 
RNA was isolated from FFPE sections using the Maxwell® RSC RNA FFPE kit (Promega,cat# 
AS1440), following manufacturer’s instructions. Briefly, 2.0 mm3 of tissue sections were placed in a 
1.5 mL Eppendorf tube and 300 µL of mineral oil was added and vortexed for 10 s. The samples were 
then heated to 80 °C for 2 min and brought to room temperature. The samples were digested and 
lysed and then pellet collected by centrifugation at 10000 × g for 20 s. The aqueous phase containing 
the pellet was heated at 56 °C for 15 min and then at 80 °C for 1 h and then incubated at room 
temperature for 30 min. Samples were DNA-digested and then loaded into the Maxwell cartridge, 
and RNA isolation was performed following the RSC RNA FFPE kit protocol in the fully automated 
system. RNA was eluted in 60 µL of nuclease-free water and stored at −80 °C until use. 
4.6. In Silico Data Mining 
In order to identify tumor-associated transcripts that were upregulated in plasma samples from 
cancer patients, we downloaded publicly available RNA sequencing data from the gene expression 
omnibus (GEO). A lung cancer data set GSE81089 comprising of both early and late stage cancers was 
downloaded [46]. The data set was composed of 199 NSCLC fresh frozen samples and 19 paired non-
tumor lung tissues. 
4.7. Total cfRNA Sequencing 
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Total RNA sequencing libraries were prepared from 450 pg of total cfRNA using the SMARTer 
Stranded Total RNA-Seq Kit v2—Pico Input Mammalian (cat# 634412, Takara Bio, Mountain View, 
CA USA ), after depletion of ribosomal RNA. RNA libraries were sequenced on an Illumina Novaseq 
6000 with 100 bp paired end read. Fastq files were quality checked with the Fastqc tool, and the reads 
were trimmed with Trimmomatic tool. Reads were mapped to the human genome (Grch 38), and 
features were quantified by means of Htseq counts. Gene expression matrices with raw counts were 
processed with Deseq2 [47] for differential gene expression and validated with edgeR and LIMMA [48,49]. 
4.8. cfRNA Transcript Deconvolution 
Cell-type cfRNA signal deconvolution was performed using reference maps from 45 different 
cell types, as previously described [50]. A complete list of all cell types included in the deconvolution 
is presented in Supplementary Table S3. We then used random forest ensemble classifier to rank the 
importance of cell type signals differentiating patient and healthy samples as previously described 
[51]. Hierarchical clustering and statistical test (Wilcoxon-Mann-Whitney U test) were performed in 
R environment. 
4.9. Transcript Quantification by RT-ddPCR  
Two transcripts, POU6F2-AS2 and AC022126.1, both of which had no measurable transcripts in 
the healthy donors in the cfRNA-seq data, were further analyzed. One of these two transcripts, 
POU6F2-AS2 has previously been associated with cancer pathogenesis. Circulating levels of POU6F2-
AS2 and AC022126.1 transcripts were measured by means of RT-ddPCR using the 1-Step RT-ddPCR 
Advanced Kit for Probes (Bio-Rad, Hercules, CA, USA) in samples from our validation cohort, which 
included 45 stage IV lung cancer patients, 39 stage I–III lung cancer patients, 20 PDAC, 22 bladder 
cancer, and more than 65 healthy control samples. Samples from the validation cohort were both 
plasma and serum. All reactions were performed in duplicates using 2 µL of cfRNA from each 
sample. The reaction components were constituted following manufacturers instruction to a final 
volume of 22 µL, of which 20 µL were used for droplet generation in a QX100™/QX200™ droplet 
generator (Bio-Rad). RT-ddPCR reactions were performed in a C1000 Touch™ thermocycler (Bio-
rad), and droplets were read in a QX100™/QX200™ droplet reader (Bio-Rad). The raw transcript 
concentration (copies/20µL reaction) was used to determine the absolute transcript load per ml of 
plasma/serum using the formula: 
Copies/mL = C × EV × 1000/ISV × TPV 
Where C = copies per 20 µL reaction 
 EV = elution volume 
 ISV = cfRNA input volume 
 TPV = total plasma/serum volume used of cfRNA isolation 
For tissue-derived samples, RT-ddPCR was performed on 4 ng of total RNA for each sample and 
data expressed per ng of RNA. 
4.10. Statistical Analysis  
Students’ t-test was used to compare the mean of two groups, and the one-way ANOVA was 
used to compare three or more groups. Categorical data was analyzed by Fishers’ exact test or by 
Chi-squared test. Strength of relationship between cfRNA copies and amounts was assessed by 
Person correlation. Statistical significance was set to a p value < 0.05. The diagnostic performance of 
the marker was evaluated with the ROCR package [52]. Data analysis was performed in the R version 
3.6-environment and Graphpad prism version 8.3 (GraphPad Software, Inc, La Jolla California USA).  
5. Conclusions 
We provided evidence on the utility of cfRNA for early detection of solid tumors irrespective of 
mutation status and identified candidate transcripts with plasma/tissue mirror images. Our findings 
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support further validation of cfRNA detection by RT-ddPCR as a biomarker for early detection of 
solid cancers. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Total cfRNA 
sequencing quality control as estimated by STAR and RSEQC, Figure S2: Tissue expression of HOTAIRM1 and 
MALAT1 in lung cancer tissue and non-tumor lung tissue Figure S3: Diagnostic performance of POU6F2-AS2 in 
NSCLC and serum total cfRNA in PDAC, Figure S4: Association between total cfRNA concentration and 
POU6F2-AS2 copies in plasma and serum, Figure S5: Total cfRNA yield is higher in serum compared with 
plasma, Figure S6: Transcript expression data for HOTAIRM1, MALAT1 and POU6F2-AS2 in cfRNA and the 
TCGA data set.  
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